Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication

NCT05262218 is registered in ClinicalTrials.gov with Palobiofarma SL as lead sponsor.

NCT NCT05262218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication
Lead sponsor
Palobiofarma SL
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2021
Completion date
April 9, 2024
Enrollment
174 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

copd